Evidence map›Paper›PMID 39137489›Full record

ReviewOral oncology2024

Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders.

Nourhan I Hussein, Andrea H Molina, Gemalene M Sunga, Moran Amit, Yu Leo Lei, Xiao Zhao, Jeffrey D Hartgerink, Andrew G Sikora, Simon Young

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Oral oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Nourhan I HusseinKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA.
Andrea H MolinaKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA.
Gemalene M SungaKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA; Department of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
Moran AmitDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
Yu Leo LeiDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
Xiao ZhaoDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
Jeffrey D HartgerinkDepartment of Chemistry and Department of Bioengineering, Rice University, 6500 Main St, BRC-319, Houston, TX 77030, USA.
Andrew G SikoraDepartment of Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, 1400 Pressler St, Pickens-1550, Houston, TX 77030, USA.
Simon YoungKatz Department of Oral and Maxillofacial Surgery, The University of Texas Health Science Center at Houston, School of Dentistry, 7500 Cambridge St, SOD-6510, Houston, TX 77054, USA. Electronic address: simon.young@uth.tmc.edu.

Funding

Restoring the Immunogenicity of Head and Neck CancerR01DE026728 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Yu Leo Lei, James J. Moon · 2018 to 2026
$4.3M
NRSA Training CoreTL1TR003169 · NCATS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI CHANDRA, JOYA, FROST, JEFFREY A. · 2019 to 2023
$3.7M
SynerGel: A Novel Tumor Microenvironment-Modulating Hydrogel for Local ImmunotherapyR01DE030140 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YOUNG, SIMON · 2021 to 2025
$3.0M
Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral PremalignancyU01DE033330 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Steven Bennett Chinn, Yu Leo Lei · 2023 to 2026
$2.7M
NCATS NIH HHS TL1 TR003169NIDCR NIH HHS R01 DE026728NIDCR NIH HHS R01 DE030140NIDCR NIH HHS U01 DE033330
6 · The paper itself

Abstract

Immunotherapy has developed into an important modality of modern cancer treatment. Unfortunately, checkpoint inhibitor immunotherapies are currently delivered systemically and require frequent administration, which can result in toxicity and severe, sometimes fatal, adverse events. Localized delivery of immunomodulators for oral cancer and oral potentially malignant disorders offers the promise of maximum therapeutic potential and reduced systemic adverse effects. This review will discuss the limitations of current standard-of-care systemic therapies and highlight research advances in localized, intratumoral delivery platforms for immunotherapy for oral cancer and oral potentially malignant disorders.

Indexed as

Mouth NeoplasmsDrug Delivery SystemsHumansImmunologic FactorsImmunomodulating AgentsImmunotherapyImmunologic FactorsImmunomodulating AgentsBiomaterialsCancerImmunotherapyOral cancerOral potentially malignant disordersOral squamous cell carcinoma

Identifiers

PMID39137489
PMCPMC11879773

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.